Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Parkinson's Disease

Free Subscription 01.06.2026 2 Ann Neurol 1 J Biol Chem 4 J Neural Transm (Vienna) 1 Lancet 6 Mov Disord 1 Nat Med 1 PLoS Comput Biol 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. CONTI M, D'Onofrio V, Lorenzon L, Grassi LL, et al
   Frequency- and Network-Specific Changes in Functional Connectivity Reflect Pathophysiological Mechanisms across Parkinson's Disease Stages.
   Ann Neurol. 2026 May 27. doi: 10.1002/ana.78262.
   PubMed         Abstract available
   
   
2. DINESH D, Morgan XC, Jensen J, Bjornevik K, et al
   Shotgun Metagenomic Profiling of the Gut Virome in Prodromal and Confirmed Parkinson's Disease.
   Ann Neurol. 2026 May 27. doi: 10.1002/ana.78243.
   PubMed         Abstract available
   
   

   
   J Biol Chem

3. HOU K, Chen J, Xie Y, Liu T, et al
   p53 regulates mitochondrial function and alpha-synuclein aggregation in Parkinson's disease.
   J Biol Chem. 2026 May 23:113184. doi: 10.1016/j.jbc.2026.113184.
   PubMed         Abstract available
   
   

   
   J Neural Transm (Vienna)

4. SZASZ JA, Blesneag AV, Dan TF, Constantin VA, et al
   Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study.
   J Neural Transm (Vienna). 2026 May 29. doi: 10.1007/s00702-026-03182.
   PubMed         Abstract available
   
   
5. AZIZI Z, Setti A, Bruno V, Prehn JHM, et al
   Beyond motor: a systematic review of multisensory integration deficits in Parkinson's disease.
   J Neural Transm (Vienna). 2026 May 29. doi: 10.1007/s00702-026-03184.
   PubMed         Abstract available
   
   
6. RODRIGUEZ-ANTIGUEDAD J, Puig-Davi A, Franch-Marti C, Bojtos L, et al
   Parkinson's disease-subjective cognitive decline and health-related quality of life.
   J Neural Transm (Vienna). 2026 May 29. doi: 10.1007/s00702-026-03183.
   PubMed         Abstract available
   
   
7. HIROSE R, Matsuura K, Ii Y, Kajikawa H, et al
   Comparison of neuromelanin-sensitive magnetic resonance imaging using different magnetic resonance protocols on the same patients with Parkinson's disease.
   J Neural Transm (Vienna). 2026 May 26. doi: 10.1007/s00702-026-03179.
   PubMed         Abstract available
   
   

   
   Lancet

8. NIKOLCHEVA T, Pagano G, Anzures-Cabrera J, Trundell D, et al
   Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
   Lancet. 2026;407:2227-2240.
   PubMed         Abstract available
   
   

   
   Mov Disord

9. ROWE S, Evans A, Kayhanian S, Buttery PC, et al
   Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.
   Mov Disord. 2026 May 28. doi: 10.1002/mds.70378.
   PubMed         Abstract available
   
   
10. THEVATHASAN W, Petoe M
    The Place of Adaptive Deep Brain Stimulation in Parkinson's Disease: Spatial before Temporal Optimization.
    Mov Disord. 2026 May 26. doi: 10.1002/mds.70368.
    PubMed        
    
    
11. LIN Z, Zeng Z, Pan Y, Huang P, et al
    Deep Brain Stimulation of the Posterior Subthalamic Area and the Subthalamic Nucleus in Tremor-Dominant Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2026 May 24. doi: 10.1002/mds.70363.
    PubMed         Abstract available
    
    
12. CAMPESE N, Qamar MA, Chiriac MA, Gobel G, et al
    Types of Pain in Multiple System Atrophy.
    Mov Disord. 2026;41:1221-1232.
    PubMed         Abstract available
    
    
13. AGIN-LIEBES J, Haimovich A, Griep R, Hatcher NG, et al
    Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers.
    Mov Disord. 2026;41:1304-1309.
    PubMed         Abstract available
    
    
14. KAMO H, Cagle JN, Johnson KA, Wong JK, et al
    Contrasting Effects of Deep Brain Stimulation and Intravenous Levodopa on Local Field Potentials.
    Mov Disord. 2026;41:1152-1162.
    PubMed         Abstract available
    
    

    
    Nat Med

15. 
    Gut microbiome screens could identify risk of Parkinson's disease years before symptoms appear.
    Nat Med. 2026 May 28. doi: 10.1038/s41591-026-04458.
    PubMed        
    
    

    
    PLoS Comput Biol

16. LI J, Li Y, Lin S, Rao J, et al
    A prototype-augmented graph representation learning framework for identifying brain disorder-associated genes and facilitating drug repurposing.
    PLoS Comput Biol. 2026;22:e1014323.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

17. DESJARDINS C, de Saint Vaulry H, Rosset C, Salardaine Q, et al
    Six-month outcomes of subcutaneous foslevodopa/foscarbidopa according to initiation setting in advanced Parkinson's disease: A retrospective cohort study.
    Rev Neurol (Paris). 2026 May 27:S0035-3787(26)00531.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum